{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:26:54Z","timestamp":1791440814520,"version":"4.3.3"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":836,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:00:00Z","timestamp":1697846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"The Swedish-Norwegian Foundation for Equine Research","award":["H-19-47-479"],"award-info":[{"award-number":["H-19-47-479"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Decreasing hyperinsulinemia is crucial in preventing laminitis in insulin dysregulated (ID) horses. Complementary pharmacological treatments that efficiently decrease postprandial hyperinsulinemia in ID horses are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Compare short-term effects of canagliflozin vs placebo on glucose and insulin responses to an oral sugar test (OST) as well as the effects on body weight and triglyceride concentrations in horses with ID.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Sixteen privately-owned ID horses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-center, randomized, double-blind, placebo-controlled, parallel design study. The horses were randomized (ratio 1:1) to either once daily PO treatment with 0.6\u2009mg\/kg canagliflozin or placebo. The study consisted of an initial 3-day period for obtaining baseline data, a 3-week double-blind treatment period at home, and a 3-day follow-up period similar to the initial baseline period but with continued double-blind treatment. Horses were subjected to an 8-sample OST in the morning of the third day on both visits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Maximal geometric least square (LS) mean insulin concentration (95% confidence interval [CI]) during the OST decreased after 3\u2009weeks of canagliflozin treatment compared with placebo (83.2; 55.4-125.0 vs 215.2; 143.2-323.2 \u03bcIU\/mL). The geometric LS mean insulin response (insulin AUC0-180) for canagliflozin-treated horses was &amp;gt;66% lower compared with placebo. Least square mean body weight decreased by 11.1 (4-18.1) kg and LS mean triglyceride concentrations increased by 0.99 (0.47-1.5) mmol\/L with canagliflozin treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Canagliflozin is a promising drug for treatment of ID horses that requires future studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.16906","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T04:33:57Z","timestamp":1697862837000},"page":"2520-2528","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Short-term effects of canagliflozin on glucose and insulin responses in insulin dysregulated horses: A randomized, placebo-controlled, double-blind, study"],"prefix":"10.1093","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6124-4015","authenticated-orcid":false,"given":"Sanna","family":"Lind\u00e5se","sequence":"first","affiliation":[{"name":"Swedish University of Agricultural Sciences Department of Clinical Sciences, , Uppsala,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Nostell","sequence":"additional","affiliation":[{"name":"Swedish University of Agricultural Sciences Department of Clinical Sciences, , Uppsala,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Forslund","sequence":"additional","affiliation":[{"name":"Uppsala University Department of Women's and Children's Health, , Uppsala,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bergsten","sequence":"additional","affiliation":[{"name":"Uppsala University Department of Women's and Children's Health, , Uppsala,","place":["Sweden"]},{"name":"Uppsala University Department of Medical Cell Biology, , Uppsala,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9981-6365","authenticated-orcid":false,"given":"Johan","family":"Br\u00f6jer","sequence":"additional","affiliation":[{"name":"Swedish University of Agricultural Sciences Department of Clinical Sciences, , Uppsala,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,1]]},"reference":[{"key":"2026021401280221900_jvim16906-bib-0001","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.tvjl.2018.03.008","article-title":"Insulinaemic and glycaemic responses to three forages in ponies","volume":"235","author":"Carslake","year":"2018","journal-title":"Vet J"},{"key":"2026021401280221900_jvim16906-bib-0002","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/jvim.14799","article-title":"Relationship between \u03b2-cell response and insulin sensitivity in horses based on the oral sugar test and the euglycemic hyperinsulinemic clamp","volume":"31","author":"Lind\u00e5se","year":"2017","journal-title":"J Vet Intern Med"},{"key":"2026021401280221900_jvim16906-bib-0003","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tvjl.2017.11.011","article-title":"Paradigm shifts in understanding equine laminitis","volume":"231","author":"Patterson-Kane","year":"2018","journal-title":"Vet J"},{"key":"2026021401280221900_jvim16906-bib-0004","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/jvim.15423","article-title":"ECEIM consensus statement on equine metabolic syndrome","volume":"33","author":"Durham","year":"2019","journal-title":"J Vet Intern Med"},{"key":"2026021401280221900_jvim16906-bib-0005","article-title":"Pharmacodynamic effects of pioglitazone on high molecular weight adiponectin concentrations and insulin response after oral sugar in equids","volume":"82","author":"Legere","year":"2019","journal-title":"J Equine Vet"},{"key":"2026021401280221900_jvim16906-bib-0006","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tvjl.2011.01.015","article-title":"The effect of oral metformin on insulin sensitivity in insulin-resistant ponies","volume":"191","author":"Tinworth","year":"2012","journal-title":"Vet J"},{"key":"2026021401280221900_jvim16906-bib-0007","article-title":"The effect of pre-dosing with metformin on the insulin response to oral sugar in insulin-dysregulated horses","author":"Colmer","year":"2023","journal-title":"Equine Vet J"},{"key":"2026021401280221900_jvim16906-bib-0008","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s40265-017-0801-6","article-title":"Canagliflozin: a review in type 2 diabetes","volume":"77","author":"Deeks","year":"2017","journal-title":"Drugs"},{"key":"2026021401280221900_jvim16906-bib-0009","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.2337\/db17-1278","article-title":"Endogenous glucose production and hormonal changes in response to Canagliflozin and Liraglutide combination therapy","volume":"67","author":"Martinez","year":"2018","journal-title":"Diabetes"},{"key":"2026021401280221900_jvim16906-bib-0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203655","article-title":"The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies","volume":"13","author":"Meier","year":"2018","journal-title":"PloS One"},{"key":"2026021401280221900_jvim16906-bib-0011","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12917-019-1811-2","article-title":"The efficacy and safety of velagliflozin over 16\u2009weeks as a treatment for insulin dysregulation in ponies","volume":"15","author":"Meier","year":"2019","journal-title":"BMC Vet Res"},{"issue":"6","key":"2026021401280221900_jvim16906-bib-0012","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13028-016-0246-z","article-title":"A modified oral sugar test for evaluation of insulin and glucose dynamics in horses","volume":"58","author":"Lind\u00e5se","year":"2016","journal-title":"Acta Vet Scand"},{"key":"2026021401280221900_jvim16906-bib-0013","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00580-011-1284-6","article-title":"Evaluation of an equine-optimized enzyme-linked immunosorbent assay for serum insulin measurement and stability study of equine serum insulin","volume":"21","author":"\u00d6berg","year":"2012","journal-title":"Comp Clin Path"},{"key":"2026021401280221900_jvim16906-bib-0014","doi-asserted-by":"crossref","first-page":"204","DOI":"10.15232\/S1080-7446(15)30475-7","article-title":"A comparison of methodologies for measuring glucose concentrations in the horse","volume":"27","author":"Slough","year":"2011","journal-title":"Prof Anim Sci"},{"key":"2026021401280221900_jvim16906-bib-0015","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2337\/diacare.18.2.245","article-title":"The use of areas under curves in diabetes research","volume":"18","author":"Allison","year":"1995","journal-title":"Diabetes Care"},{"key":"2026021401280221900_jvim16906-bib-0016","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/dom.13005","article-title":"Review of methods for measuring \u03b2-cell function: design considerations from the restoring insulin secretion (RISE) consortium","volume":"20","author":"Hannon","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026021401280221900_jvim16906-bib-0017","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2337\/dc08-1478","article-title":"Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels","volume":"32","author":"Utzschneider","year":"2009","journal-title":"Diabetes Care"},{"key":"2026021401280221900_jvim16906-bib-0018","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002264","article-title":"Shape of the OGTT glucose response curve: relationship with \u03b2-cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin","volume":"9","author":"Utzschneider","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2026021401280221900_jvim16906-bib-0019","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/bmj.323.7321.1123","article-title":"Analysing controlled trials with baseline and follow up measurements","volume":"323","author":"Vickers","year":"2001","journal-title":"BMJ"},{"key":"2026021401280221900_jvim16906-bib-0020","doi-asserted-by":"crossref","first-page":"511","DOI":"10.5455\/OVJ.2022.v12.i4.14","article-title":"Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis","volume":"12","author":"Kellon","year":"2022","journal-title":"Open Vet J"},{"key":"2026021401280221900_jvim16906-bib-0021","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/eve.13738","article-title":"Preliminary observations on the use of ertugliflozin in the management of hyperinsulinaemia and laminitis in 51 horses: a case series","volume":"35","author":"Sundra","year":"2022","journal-title":"Equine Vet Educ"},{"key":"2026021401280221900_jvim16906-bib-0022","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes","volume":"32","author":"Abdul-Ghani","year":"2011","journal-title":"Endocr Rev"},{"key":"2026021401280221900_jvim16906-bib-0023","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2147\/DDDT.S50773","article-title":"Update on developments with SGLT2 inhibitors in the management of type 2 diabetes","volume":"8","author":"Nauck","year":"2014","journal-title":"Drug des Devel Ther"},{"key":"2026021401280221900_jvim16906-bib-0024","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"2026021401280221900_jvim16906-bib-0025","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","article-title":"Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2\u2009weeks in patients with type 2 diabetes mellitus","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"2026021401280221900_jvim16906-bib-0026","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/jvp.12467","article-title":"Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats","volume":"41","author":"Hoenig","year":"2018","journal-title":"J Vet Pharmacol Ther"},{"key":"2026021401280221900_jvim16906-bib-0027","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1038\/ki.2010.512","article-title":"Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans","volume":"2011","author":"List","year":"2011","journal-title":"Kidney Int Suppl"},{"key":"2026021401280221900_jvim16906-bib-0028","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/evj.13110","article-title":"The effect of insulin infusion on heart rate and systemic blood pressure in horses with equine metabolic syndrome","volume":"51","author":"Nostell","year":"2019","journal-title":"Equine Vet J"},{"key":"2026021401280221900_jvim16906-bib-0029","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1210\/jc.2017-01838","article-title":"Empagliflozin treatment is associated with improved \u03b2-cell function in type 2 diabetes mellitus","volume":"103","author":"Al Jobori","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2026021401280221900_jvim16906-bib-0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258054","article-title":"SGLT2 inhibitors therapy protects glucotoxicity-induced \u03b2-cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress","volume":"17","author":"Shyr","year":"2022","journal-title":"PloS One"},{"key":"2026021401280221900_jvim16906-bib-0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvjl.2023.105967","article-title":"Equine metabolic syndrome: role of the enteroinsular axis in the insulin response to oral carbohydrate","volume":"294","author":"de Laat","year":"2023","journal-title":"Vet J"},{"key":"2026021401280221900_jvim16906-bib-0032","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s13300-018-0449-6","article-title":"A randomized controlled trial of dapagliflozin plus once-weekly exenatide versus placebo in individuals with obesity and without diabetes: metabolic effects and markers associated with bodyweight loss","volume":"9","author":"Pereira","year":"2018","journal-title":"Diabetes Ther"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/37\/6\/2520\/66895690\/jvim16906.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/37\/6\/2520\/66895690\/jvim16906.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T06:28:13Z","timestamp":1771050493000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/37\/6\/2520\/8483292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.16906","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,11,1]]},"assertion":[{"value":"2023-07-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}